长效基础胰岛素：近期获批药物的综述。
Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.
机构信息
From the University of New Mexico College of Pharmacy, Department of Pharmacy Practice and Administrative Sciences, Albuquerque, NM.
University of New Mexico Hospital, Department of Pharmacy, Albuquerque, NM.
出版信息
Cardiol Rev. 2019 Sep/Oct;27(5):260-266. doi: 10.1097/CRD.0000000000000266.
Long-acting basal insulins are used for the management of both type 1 and type 2 diabetes mellitus. Long-acting basal insulins were developed utilizing recombinant DNA technology and have been available since 2000 with the approval of insulin glargine U-100 followed by insulin detemir in 2005. In recent years, diabetes management has become more complex with the approval of insulin glargine U-300 and insulin degludec U-100 and U-200. Both insulin glargine U-300 and insulin degludec have been compared with insulin glargine U-100 and have demonstrated longer durations of action, as well as lower rates of hypoglycemia. This review discusses the Food and Drug Administration-approved long-acting insulins with a focus on recently approved agents and their efficacy and safety compared with the first long-acting basal insulins.
长效基础胰岛素用于 1 型和 2 型糖尿病的治疗。长效基础胰岛素利用重组 DNA 技术开发，自 2000 年批准 U-100 胰岛素甘精以来，经过 2005 年批准胰岛素地特胰岛素，已经上市。近年来，随着 U-300 胰岛素甘精和 U-100、U-200 胰岛素德谷胰岛素的批准，糖尿病管理变得更加复杂。U-300 胰岛素甘精和 U-100 胰岛素德谷胰岛素均已进行比较，结果显示作用持续时间更长，低血糖发生率更低。本综述讨论了美国食品药品监督管理局批准的长效胰岛素，重点是最近批准的药物及其与第一代长效基础胰岛素相比的疗效和安全性。
Zotero 插件